HomeCompareBAGAX vs JNJ

BAGAX vs JNJ: Dividend Comparison 2026

BAGAX yields 96.66% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BAGAX wins by $33953479481069.43M in total portfolio value
10 years
BAGAX
BAGAX
● Live price
96.66%
Share price
$6.56
Annual div
$6.34
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33953479481069.46M
Annual income
$33,886,135,663,349,223,000.00
Full BAGAX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BAGAX vs JNJ

📍 BAGAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAGAXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAGAX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAGAX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAGAX
Annual income on $10K today (after 15% tax)
$8,216.39/yr
After 10yr DRIP, annual income (after tax)
$28,803,215,313,846,837,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BAGAX beats the other by $28,803,215,313,846,833,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAGAX + JNJ for your $10,000?

BAGAX: 50%JNJ: 50%
100% JNJ50/50100% BAGAX
Portfolio after 10yr
$16976739740534.74M
Annual income
$16,943,067,831,674,614,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BAGAX
No analyst data
Altman Z
1.2
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAGAX buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAGAXJNJ
Forward yield96.66%2.13%
Annual dividend / share$6.34$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$33953479481069.46M$30.3K
Annual income after 10y$33,886,135,663,349,223,000.00$4,689.40
Total dividends collected$33949058472929.85M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BAGAX vs JNJ ($10,000, DRIP)

YearBAGAX PortfolioBAGAX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$30,033$19,332.68$10,592$272.30+$19.4KBAGAX
2$140,661$108,525.67$11,289$357.73+$129.4KBAGAX
3$1,100,580$950,073.39$12,123$472.89+$1.09MBAGAX
4$15,072,428$13,894,806.70$13,141$629.86+$15.06MBAGAX
5$371,808,121$355,680,623.42$14,408$846.81+$371.79MBAGAX
6$16,797,768,278$16,399,933,588.66$16,021$1,151.60+$16797.75MBAGAX
7$1,402,881,924,619$1,384,908,312,561.77$18,122$1,588.22+$1402881.91MBAGAX
8$217,691,667,135,638$216,190,583,476,294.90$20,930$2,228.20+$217691667.11MBAGAX
9$62,938,147,402,089,110$62,705,217,318,253,980.00$24,792$3,191.91+$62938147402.06MBAGAX
10$33,953,479,481,069,460,000$33,886,135,663,349,223,000.00$30,274$4,689.40+$33953479481069.43MBAGAX

BAGAX vs JNJ: Complete Analysis 2026

BAGAXStock

The fund normally invests at least 80% of the value of its net assets (plus any borrowings for investment purposes) in equity securities of domestic companies. It invests primarily in securities of medium and large market capitalization companies that the Adviser believes have exhibited an above average rate of earnings growth and that have prospects for above average, sustainable growth in the future. Medium and large market capitalization companies are those companies with market capitalizations generally greater than $2 billion at the time of purchase.

Full BAGAX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BAGAX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAGAX vs SCHDBAGAX vs JEPIBAGAX vs OBAGAX vs KOBAGAX vs MAINBAGAX vs ABBVBAGAX vs MRKBAGAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.